Author(s): Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, et al.
Nonmotor symptoms (NMS) of Parkinson's disease (PD) are not well recognized in clinical practice, either in primary or in secondary care, and are frequently missed during routine consultations. There is no single instrument (questionnaire or scale) that enables a comprehensive assessment of the range of NMS in PD both for the identification of problems and for the measurement of outcome. Against this background, a multidisciplinary group of experts, including patient group representatives, has developed an NMS screening questionnaire comprising 30 items. This instrument does not provide an overall score of disability and is not a graded or rating instrument. Instead, it is a screening tool designed to draw attention to the presence of NMS and initiate further investigation. In this article, we present the results from an international pilot study assessing feasibility, validity, and acceptability of a nonmotor questionnaire (NMSQuest). Data from 123 PD patients and 96 controls were analyzed. NMS were highly significantly more prevalent in PD compared to controls (PD NMS, median = 9.0, mean = 9.5 vs. control NMS, median = 5.5, mean = 4.0; Mann-Whitney, Kruskal-Wallis, and t test, P < 0.0001), with PD patients reporting at least 10 different NMS on average per patient. In PD, NMS were highly significantly more prevalent across all disease stages and the number of symptoms correlated significantly with advancing disease and duration of disease. Furthermore, frequently, problems such as diplopia, dribbling, apathy, blues, taste and smell problems were never previously disclosed to the health professionals.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/16547944
Author(s): Lee MA, Walker RW, Hildreth TJ, Prentice WM
Author(s): Bair MJ, Robinson RL, Katon W, Kroenke K
Author(s): McWilliams LA, Cox BJ, Enns MW
Author(s): Hanagasi HA, Akat S, Gurvit H, Yazici J, Emre M
Author(s): Nieoullon A
Author(s): Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, et al.
Author(s): Roh JH, Kim BJ, Jang JH, Seo WK, Lee SH, et al.
Author(s): Hara T, Hirayama M, Mizutani Y, Hama T, Hori N, et al.
Author(s): Erro R, Santangelo G, Picillo M, Vitale C, Amboni M, et al.
Author(s): Hughes AJ, Daniel SE, Kilford L, Lees AJ
Author(s): Fahn S; Parkinson Study Group
Author(s): Nie K, Zhang Y, Wang L, Zhao J, Huang Z, et al.
Author(s): Melzack R
Author(s): Cleeland CS, Ryan KM
Author(s): Smeding HM, Esselink RA, Schmand B, Koning-Haanstra M, Nijhuis I, et al.
Author(s): Ford B
Author(s): Airavaara M, Harvey BK, Voutilainen MH, Shen H, Chou J, et al.
Author(s): Ha AD, Jankovic J
Author(s): Santos-García D, Abella-Corral J, Aneiros-Díaz Á, Santos-Canelles H, Llaneza-González MA, et al.
Author(s): Yong MH, Allen JC Jr, Prakash KM, Tan EK
Author(s): Jarcho JM, Mayer EA, Jiang ZK, Feier NA, London ED
Author(s): Mylius V, Brebbermann J, Dohmann H, Engau I, Oertel WH, et al.
Author(s): Nutt JG
Author(s): Lim SY, Farrell MJ, Gibson SJ, Helme RD, Lang AE, et al.
Author(s): Romenets SR, Wolfson C, Galatas C, Pelletier A, Altman R, et al.
Author(s): Raudino F